Saturday 17 October 2026
Export ZJYL’s income statement to Excel — free account
Jin Medical International Ltd.
ZJYL Healthcare Medical Instruments & Supplies
Jin Medical International Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $20.7 million, down 12.0% from fiscal 2024.
2.08
0.08
−3.70%
Follow ZJYL
| Sep '25 | Sep '24 | Sep '23 | Dec '22 | Sep '22 | Dec '21 | Sep '21 | Sep '20 | Sep '19 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | — | — | — | — | 8 | — | — |
Altman Z-Score |
3.66 | 16.70 | 13.84 | — | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
5.16 | 7.37 | 9.51 | — | 9.87 | 10.47 | 8.51 | 6.67 | 7.87 |
Beneish M-Score |
(2.46) | (1.25) | (1.78) | — | — | — | (2.81) | (2.23) | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(6.88) | (5.70) | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF |
6.44 | (6.19) | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
1.49 | 2.06 | 2.82 | 0.00 | 1.96 | 1.96 | 1.49 | 1.07 | 1.24 |
Current Ratio |
1.86 | 2.50 | 3.49 | 0.00 | 3.31 | 3.31 | 2.38 | 1.79 | 1.83 |
Net Debt/EBITDA |
(34.79) | (6.90) | (5.40) | 0.00 | (2.84) | (1.76) | (1.93) | (0.07) | (0.10) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.72% | 14.10% |
Debt/Equity |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.25 | 0.27 |
Asset Turnover |
0.42 | 0.60 | 0.74 | 0.00 | 0.92 | 0.90 | 0.97 | 0.79 | 0.00 |
Operating CF/Net income |
2.44 | (0.33) | 1.08 | 0.00 | 0.58 | 0.00 | 2.22 | 1.13 | (0.36) |
Capex/Depreciation |
(27.24) | (4.73) | (0.46) | — | (0.11) | — | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | — | — | — | 554.00 | 41.90 | 386.30 |
| 4.10% | 14.00% | 14.68% | 0.00% | 18.26% | 19.03% | 21.20% | 20.51% | 0.00% | |
| 2.40% | 9.34% | 10.69% | 27.49% | 12.93% | 12.64% | 12.32% | 10.71% | 0.00% | |
ROIC |
0.00% | 126.69% | 24.61% | 0.00% | 16.30% | 30.79% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
4.22% | 13.55% | 12.16% | 33.97% | 18.25% | 18.25% | 20.26% | 21.49% | 34.99% |
Average Days of Receivables |
104.34 | 132.95 | 156.00 | 0.00 | 78.37 | 78.37 | 105.11 | 177.19 | 154.59 |
Research and Development Expense of Revenue |
7.53% | 6.37% | 7.78% | — | 9.86% | 0.00% | 7.55% | 7.79% | 5.55% |
Selling, General and Administrative Expense of Revenue |
18.75% | 18.58% | 11.98% | 0.00% | 11.34% | 11.34% | 10.42% | 11.62% | 9.71% |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
2.64 | 3.00 | 2.73 | — | 2.84 | 0.00 | 2.60 | 2.02 | 2.55 |
Operating CF per Share |
0.37 | (0.15) | 0.43 | — | 0.23 | — | 0.73 | 0.31 | (0.17) |
Capex per Share |
(0.85) | (0.14) | (0.01) | — | (0.01) | — | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.48) | (0.30) | 0.41 | — | 0.23 | — | 0.73 | 0.31 | (0.17) |
Cash per Share |
3.79 | 3.42 | 2.30 | — | 1.05 | 0.00 | 0.72 | 0.35 | 0.42 |
Shareholders Equity per Share |
3.78 | 3.65 | 3.30 | — | 2.26 | 0.00 | 1.75 | 1.35 | 1.34 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.78 | 3.65 | 3.30 | — | 2.26 | 0.00 | 1.75 | 1.35 | 1.34 |
Free Cash Flow |
(3.73) | (2.33) | 3.00 | — | 1.54 | — | 5.84 | 2.50 | (1.33) |
Working Capital |
20.35 | 25.66 | 22.19 | 8.47 | 13.20 | 13.20 | 10.88 | 7.96 | 8.05 |
Capital Expenditures |
(6.63) | (1.12) | (0.10) | — | (0.04) | — | (0.04) | (0.14) | (0.07) |
Net Current Asset Value |
20.35 | 25.57 | 22.19 | 8.47 | 13.20 | 13.20 | 10.88 | 7.96 | 8.05 |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.32 | 0.05 | 0.01 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.03 | 0.16 | 0.15 | — | 0.22 | 0.00 | 0.16 | 0.14 | 0.14 |
Cash ROIC |
(6.29%) | (4.21%) | 7.38% | — | 6.91% | 0.00% | 29.58% | 15.37% | (7.83%) |
Accounts Receivable Turnover |
2.86 | 2.76 | 2.34 | 0.00 | 4.66 | 3.80 | 3.00 | 1.96 | 0.00 |
Accounts Payable Turnover |
4.67 | 4.37 | 3.47 | — | 2.75 | 0.00 | 2.67 | 2.10 | 0.00 |
Inventory Turnover |
2.90 | 2.74 | 2.21 | — | 1.93 | 1.89 | 2.01 | 1.64 | 0.00 |
Average Days of Payables |
81.18 | 78.54 | 94.94 | — | 115.57 | 0.00 | 135.61 | 185.45 | 135.18 |
Days of Inventory on Hand |
122.72 | 134.89 | 141.48 | — | 188.92 | 188.92 | 178.44 | 248.11 | 162.85 |
Average Receivables |
7.24 | 8.52 | 8.47 | 6.30 | 4.12 | 5.05 | 6.92 | 8.24 | — |
Average Payables |
3.13 | 3.20 | 3.75 | — | 4.73 | — | 5.39 | 5.10 | — |
Average Inventory |
5.05 | 5.11 | 5.89 | — | 6.72 | 6.88 | 7.16 | 6.50 | — |
Average Assets |
49.58 | 39.35 | 26.92 | 10.47 | 20.94 | 21.42 | 21.36 | 20.59 | — |
Average Common Equity |
29.06 | 26.27 | 19.61 | — | 14.82 | 14.22 | 12.42 | 10.75 | — |
Columns are period end dates